


PHARMACEUTICAL 2023

SELLAS Life Sciences Group Inc. Rank 386 of 446









PHARMACEUTICAL 2023

SELLAS Life Sciences Group Inc. Rank 386 of 446



The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 14% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Net Income, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -178%, being 221% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	17,756
Cost of Goods Sold	100
Intangible Assets	1,914
Liabilities, Current	15,515
Liabilities, Non-Current	573
Other Assets	1,273
Other Compr. Net Income	0
Other Expenses	10,000
Other Liabilities	4.0
Other Net Income	649
Other Revenues	1,000
Property and Equipment	0
Research and Development	20,268
Selling, General and Administrative Expense	12,582

Output Variable	Value in 1000 USD
Assets	20,943
Liabilities	16,092
Expenses	42,950
Revenues	1,000
Stockholders Equity	4,851
Net Income	-41,301
Comprehensive Net Income	-41,301
Economic Capital Ratio	-178%

